期刊
RESVERATROL AND HEALTH
卷 1290, 期 -, 页码 37-51出版社
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12150
关键词
resveratrol; cardiovascular; grape; polyphenol; clinical trial; nutraceutical
资金
- Ministry of Economy and Competitiveness, MINECO, Spain [CICYT BFU2007-60576, ALG2011-22447]
- Fundacion Seneca (Murcia, Spain) [GERM 06 04486]
- Consolider Ingenio [CSD2007-00063]
- MINECO, Spain
- JAE-Doc contract (CSIC, Spain)
Primary prevention of cardiovascular disease (CVD) aims to avoid a first event in subjects that are at risk but have not yet been diagnosed with heart disease. Secondary prevention of CVD aims to avoid new events in patients with established heart disease. Both approaches involve clinical intervention and implementation of healthy lifestyles. The grape and wine polyphenol resveratrol (3,5,4'-trihydroxy-trans-stilbene) has shown cardioprotective benefits in humans. Most of these approaches deal with rather high doses and short follow-ups, and do not address the issue of long-term resveratrol consumption safety, especially in medicated individuals. Here, we review the trials conducted with resveratrol in patients at risk for or with established CVD, focusing on the two longest human clinical trials reported so far (1-year follow-up). We also discuss the expectations for resveratrol from a dietary and clinical perspective in relation to CVD. However, statistically significant changes in CVD-risk markers do not necessarily equal clinical significance in the daily care of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据